Drug firm Aurobindo Pharma said on Tuesday that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market a drug used for dementia treatment in the US. The drug, which has an estimated market size of $26.7 million, is expected to be launched in the first quarter of the next fiscal, it added. 